ADB-P7AICA is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products, first identified by the DEA in early 2021.[1][2]
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H28N4O2 |
Molar mass | 344.459 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ "Announcement of a Newly Identified Synthetic Cannabinoid ADB-P7AICA" (PDF). Drug Enforcement Administration Toxicology Testing Program. U.S. Department of Justice. 22 February 2021.
- ^ Sparkes E, Cairns EA, Kevin RC, Lai F, Grafinger KE, Chen S, et al. (February 2022). "Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA". RSC Medicinal Chemistry. 13 (2): 156–174. doi:10.1039/d1md00242b. PMC 8864554. PMID 35308023.